Loading...
Market
Volume of breast cancer recurrence tests conducted in first year of availability?
5
Resolution / Starting Odds
0-10,000 tests • 33%
10,001-50,000 tests • 33%
50,001+ tests • 33%
Company reports or market research publications
Story
New Ultra-Sensitive Blood Test from London's Institute Predicts Breast Cancer Recurrence with 100% Accuracy
Jun 2, 2024, 02:55 PM
Researchers in the UK have developed an ultra-sensitive blood test that can predict if breast cancer will return years before it shows up on scans. This breakthrough test, developed by scientists at London's Institute of Cancer Research, boasts 100% accuracy and detects circulating tumor DNA. It allows for early intervention, potentially preventing the disease from becoming incurable. The test has been hailed as incredibly exciting and marks a significant advancement in the early detection of breast cancer recurrence.
View original story
Similar markets
0-10% • 25%
11-25% • 25%
26-50% • 25%
More than 50% • 25%
Below 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
Above 50% • 25%
$0-100 million • 25%
$101-500 million • 25%
$501 million - $1 billion • 25%
Over $1 billion • 25%
Below 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
Above 50% • 25%
High in urban areas • 25%
High in rural areas • 25%
Uniform across regions • 25%
Low overall adoption • 25%
EU • 33%
Asia • 33%
South America • 33%
Over 100,000 users • 25%
50,000 to 100,000 users • 25%
10,000 to 49,999 users • 25%
Under 10,000 users • 25%
Below 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
Above 75% • 25%
Less than 10% adoption • 25%
10% to 25% adoption • 25%
26% to 50% adoption • 25%
More than 50% adoption • 25%
No competitors • 33%
1-2 competitors • 33%
3 or more competitors • 33%
None • 33%
Some provinces • 33%
All provinces • 33%
No Change • 33%
Lowered to 45 • 33%
Lowered to 40 • 33%